Eurofins Scientific earnings consensus, analysts weigh growth prospects
23.06.2026 - 14:18:45 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:16.
Eurofins Scientific SE (FR0014000MR3) sits in the European laboratory-testing sector alongside listed peers such as SGS and Bureau Veritas, with its shares trading in Paris and on other European venues. Analyst consensus on the stock outlines earnings expectations and growth prospects for the current year, according to recent data compilations from research aggregators.
How analysts view Eurofins
MarketScreener’s governance and overview page for Eurofins Scientific shows the shares at around 63 euros as of early June 2026, providing a reference point for valuation discussions in European trading. While individual broker notes are often paywalled, aggregated consensus data typically indicates a mix of Buy and Hold ratings, reflecting cautious but constructive sentiment toward the company’s earnings trajectory. This consensus clustering points to expectations of continued revenue growth, but with sensitivity to margins and cash generation in light of past expansion and investment cycles, as noted in various analyst compendiums that compare Eurofins’ profile with European testing peers.
Earnings expectations and valuation context
Consensus earnings-per-share estimates for Eurofins Scientific in 2026, as collated by financial data providers, generally imply modest year-on-year growth from the prior reported period, consistent with a mature but still expanding testing and inspection franchise. Valuation multiples derived from these estimates, such as forward price-to-earnings ratios, place Eurofins in a range broadly comparable to other European laboratory and inspection firms, with some analysts highlighting its diversified portfolio as a partial justification for a premium, while others point to leverage and capex needs as constraints. A number of research houses across Europe and the US cover the stock, and their updates typically reference the competitive position versus SGS, Bureau Veritas, Intertek and regional peers, anchoring Eurofins firmly within the wider European mid-cap growth universe, even though it is not part of headline indices like the CAC 40.
Background and price data on Eurofins Scientific
For more news, governance information and market data on Eurofins Scientific, the internal topic page and the company’s investor relations site provide detailed filings and updates.
The business behind the estimates
Eurofins Scientific generates revenue primarily from testing, inspection and certification services across pharmaceuticals, food, environment and clinical diagnostics, according to its corporate description and investor materials. The group’s model relies on a network of laboratories providing standardized, high-throughput testing for clients ranging from global pharmaceutical companies to food producers and public health authorities, which diversifies its income streams and underpins the earnings profiles that analysts model in their forecast tables.
Where the shares trade today
Eurofins Scientific shares (FR0014000MR3) most actively trade on Euronext Paris, where investors monitor volumes, spreads and closing prices in euros alongside the consensus estimates and target prices published by research houses and financial data providers.
Eurofins Scientific key data
- Company: Eurofins Scientific SE
- ISIN: FR0014000MR3
- WKN: (not live-verified)
- Ticker: ERF (Paris, indicative)
- Trading venue: Euronext Paris
- Price (as of latest available close): 63.00 EUR
- Market cap: based on 63.00 EUR share price and outstanding shares as per investor materials, giving a multi-billion euro valuation range
- Sector / industry: Testing, inspection and certification / Life sciences services
- Index membership: European mid-cap universe, not in headline CAC 40 index
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell securities. Data and estimates are based on sources believed to be reliable but cannot be guaranteed; investors should conduct their own research and consider their individual financial situation.
